Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

ED50 and ED95 of Intranasal Dexmedetomidine in Pediatric Patients Undergoing Transthoracic Echocardiography Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02780427
Recruitment Status : Recruiting
First Posted : May 23, 2016
Last Update Posted : August 2, 2019
Sponsor:
Information provided by (Responsible Party):
Wenhua Zhang, Guangzhou Women and Children's Medical Center

Brief Summary:
The median effective dose (ED50) and ED95 of intranasal dexmedetomidine as a single bolus have not been described for sedation in children undergoing transthoracic echocardiography (TEE) study. This information is important to compare agents and to determine the most effective sedative dose. The investigators performed a two-stage study to determine the ED50 and the ED95 of intranasal dexmedetomidine to investigate age-related differences in participants undergoing transthoracic echocardiography study.

Condition or disease Intervention/treatment Phase
Patients for Transthoracic Echocardiography Unknown Diagnosis Drug: intranasal dexmedetomidine Phase 4

Detailed Description:
The investigators performed a two-stage study to determine the ED50 and the ED95 of intranasal dexmedetomidine in children undergoing transthoracic echocardiography study. In phase 1, 120 participants were randomized in a Dixon-Massey study to describe the minimum local sedative dose. In phase 2, a further 160 participants were randomly allocated to receive sedation with doses in the upper dose-response range to define the ED95

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 320 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: ED50 and ED95 of Intranasal Dexmedetomidine in Pediatric Patients Undergoing Transthoracic Echocardiography Study
Estimated Study Start Date : December 2019
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : December 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: 1-6 months (Group 1) Drug: intranasal dexmedetomidine
Phase 1, Children received a bolus of intranasal dexmedetomidine which adjusted by the "Dixon up-and-down method for TEE study. The first child received 2.5 mcg/kg of intranasal dexmedetomidine dose (100mcg/ml), and the dose varied by 0.1 mcg/kg according to the up-and-down method Phase 2 was a dose-escalation study. After interim analysis of the phase 1 results, four dose levels above the calculated ED50 were defined. Dose spacing was set at 0.25 mcg/kg of intranasal dexmedetomidine consistent with the re-estimated standard deviation (SD).

Active Comparator: 7-12 months (Group 2) Drug: intranasal dexmedetomidine
Phase 1, Children received a bolus of intranasal dexmedetomidine which adjusted by the "Dixon up-and-down method for TEE study. The first child received 2.5 mcg/kg of intranasal dexmedetomidine dose (100mcg/ml), and the dose varied by 0.1 mcg/kg according to the up-and-down method Phase 2 was a dose-escalation study. After interim analysis of the phase 1 results, four dose levels above the calculated ED50 were defined. Dose spacing was set at 0.25 mcg/kg of intranasal dexmedetomidine consistent with the re-estimated standard deviation (SD).

Active Comparator: 13-18 months (Group 3) Drug: intranasal dexmedetomidine
Phase 1, Children received a bolus of intranasal dexmedetomidine which adjusted by the "Dixon up-and-down method for TEE study. The first child received 2.5 mcg/kg of intranasal dexmedetomidine dose (100mcg/ml), and the dose varied by 0.1 mcg/kg according to the up-and-down method Phase 2 was a dose-escalation study. After interim analysis of the phase 1 results, four dose levels above the calculated ED50 were defined. Dose spacing was set at 0.25 mcg/kg of intranasal dexmedetomidine consistent with the re-estimated standard deviation (SD).

Active Comparator: 19-24 months (Group 4) Drug: intranasal dexmedetomidine
Phase 1, Children received a bolus of intranasal dexmedetomidine which adjusted by the "Dixon up-and-down method for TEE study. The first child received 2.5 mcg/kg of intranasal dexmedetomidine dose (100mcg/ml), and the dose varied by 0.1 mcg/kg according to the up-and-down method Phase 2 was a dose-escalation study. After interim analysis of the phase 1 results, four dose levels above the calculated ED50 were defined. Dose spacing was set at 0.25 mcg/kg of intranasal dexmedetomidine consistent with the re-estimated standard deviation (SD).




Primary Outcome Measures :
  1. The ED50 doses for intranasal dexmedetomidine [ Time Frame: up to 0.5 hours after transthoracic echocardiography ]
    Phase 1: The starting dose of dexmedetomidine was 2.5 mcg/kg. These doses varied by 0.1 mcg/kg, according to the up-and-down method 18. If the detected MOAA/S score was >3 within 45 minutes after intranasal administration, or clinically adequate diagnostic-quality images could not be acquired, sedation was considered a failure; and the dexmedetomidine dose was increased by 0.1 mcg/kg in the next patient of the same age group. In contrast, if the detected MOAA/S score was ≤3 and the acquisition of clinically adequate diagnostic-quality images was possible, the sedation was considered successful; and the dexmedetomidine dose was decreased by 0.1 mcg/kg in the next patient o

  2. The ED95 doses for intranasal dexmedetomidine [ Time Frame: up to 0.5 hours after transthoracic echocardiography ]

    Phase 2 was a dose-escalation study. After interim analysis of the phase 1 results, four dose levels above the calculated ED50 were defined. Dose spacing was set at 0.3 mcg/kg of intranasal dexmedetomidine consistent with the re-estimated standard deviation (SD). Defined levels were set at about 2.5, 2.75, 3.0, and 3.25 mcg/kg of intranasal dexmedetomidine. Criteria for success and failure were identical to those in phase 1.

    Successful sedation was defined as a MOAA/S score between 0-3 and allowed the acquisition of clinically adequate diagnostic-quality images, while failure was defined as a MOAA/S score >3 within 45 minutes or clinically adequate diagnostic-quality images could not be acquired


  3. Score of physical movement [ Time Frame: up to 0.5 hours after transthoracic echocardiography ]

    Movement score was recorded by sonographers who were blinded to the sedative regimen.

    1. No movement
    2. Occasional, slight movement
    3. Frequent, slight movement
    4. Vigorous movement limited to extremities
    5. Vigorous movement, including torso and head


Secondary Outcome Measures :
  1. sedation induction time [ Time Frame: up to 2 hours after drug administration ]
    Successful sedation was defined as an MOAA/S of between 0 and 3, and sedation induction time was defined as the time from drug administration to the onset of satisfactory sedation

  2. Wake -up time [ Time Frame: up to 2 hours after drug administration ]
    Children were classified as awake if the MOAA/S was between 4 and 6. Wake -up time was defined as the time from successful sedation until the time that the child awoke


Other Outcome Measures:
  1. heart rate [ Time Frame: up to 3 hours after drug administration ]
    Bradycardia was defined as a reduction in heart rate more than 20% from the baseline values

  2. Oxyhemoglobin desaturation [ Time Frame: up to 3 hours after drug administration ]
    Significant Oxyhemoglobin desaturation was defined as < 90%.

  3. non-invasive systolic blood pressure [ Time Frame: up to 3 hours after drug administration ]
    Hypotension was defined as a reduction in systolic blood pressure more than 20% from the baseline values



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   1 Month to 24 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Children, aged between one and 24 months. classified as (American Society of Anesthesiologists) ASA physical status I or II, undergoing TEE were enrolled in the study.

Exclusion Criteria:

  • Known allergy or hypersensitive reaction to dexmedetomidine
  • Organ dysfunction, and significant developmental delays or behavior problems
  • Cardiac arrhythmia
  • Known. acyanotic congenital heart disease or children after cardiac interventional procedures for follow-up examination.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02780427


Contacts
Layout table for location contacts
Contact: Wenhua Zhang, MD +8613611453199 zhangcobra@126.com
Contact: Yanting Fang, MD +8618198907630 13560358327@163.com

Locations
Layout table for location information
China, Guangdong
Department of Anesthesiology of Guangzhou Women and Children's Medical Center Recruiting
Guangzhou, Guangdong, China, 510000
Contact: Wenhua Zhang, MD    8613611453199    zhangcobra@126.com   
Contact: Yanting Fan, MD    8613560358372    849412396@qq.com   
Sponsors and Collaborators
Guangzhou Women and Children's Medical Center
Layout table for additonal information
Responsible Party: Wenhua Zhang, Director, Clinical Resesearch, Guangzhou Women and Children's Medical Center
ClinicalTrials.gov Identifier: NCT02780427    
Other Study ID Numbers: Wzhang03
First Posted: May 23, 2016    Key Record Dates
Last Update Posted: August 2, 2019
Last Verified: August 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Wenhua Zhang, Guangzhou Women and Children's Medical Center:
Dose-Response Relationship, Drug
Additional relevant MeSH terms:
Layout table for MeSH terms
Dexmedetomidine
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Adrenergic alpha-2 Receptor Agonists
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action